Literature DB >> 32829669

Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study.

Lars Vedel Kessing1, Helene Charlotte Rytgaard2, Claus Thorn Ekstrøm2, Christian Torp-Pedersen3,4,5, Michael Berk6, Thomas Alexander Gerds2.   

Abstract

Hypertension, cardiovascular diseases, and cerebrovascular diseases are associated with an increased risk of depression, but it remains unclear whether treatment with antihypertensive agents decreases or increases this risk. The effects of individual drugs are also unknown. We used Danish population-based registers to systematically investigate whether the 41 most used individual antihypertensive drugs were associated with an altered risk of incident depression. Analyses of diuretics were included for comparisons. Participants were included in the study in January 2005 and followed until December 2015. Two different outcome measures were included: (1) a diagnosis of depressive disorder at a psychiatric hospital as an inpatient or outpatient and (2) a combined measure of a diagnosis of depression or use of antidepressants. Continued use of classes of angiotensin agents, calcium antagonists, and β-blockers was associated with significantly decreased rates of depression, whereas diuretic use was not. Individual drugs associated with decreased depression included 2 of 16 angiotensin agents: enalapril and ramipril; 3 of 10 calcium antagonists: amlodipine, verapamil, and verapamil combinations; and 4 of 15 β-blockers: propranolol, atenolol, bisoprolol, and carvedilol. No drug was associated with an increased risk of depression. In conclusion, real-life population-based data suggest a positive effect of continued use of 9 individual antihypertensive agents. This evidence should be used in guiding prescriptions for patients at risk of developing depression including those with prior depression or anxiety and patients with a family history of depression.

Entities:  

Keywords:  antihypertensive agents; anxiety disorders; depressive disorder; diuretics; inflammation

Year:  2020        PMID: 32829669     DOI: 10.1161/HYPERTENSIONAHA.120.15605

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.

Authors:  Lucy Colbourne; Paul J Harrison
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

2.  Tai chi or health education for older adults with hypertension: effects on mental health and psychological resilience to COVID-19.

Authors:  Jordan N Kohn; Judith D Lobo; Emily A Troyer; Kathleen L Wilson; Gavrila Ang; Amanda L Walker; Christopher Pruitt; Meredith A Pung; Laura S Redwine; Suzi Hong
Journal:  Aging Ment Health       Date:  2022-03-21       Impact factor: 3.514

3.  Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes.

Authors:  Lucy Colbourne; Sierra Luciano; Paul J Harrison
Journal:  Transl Psychiatry       Date:  2021-05-26       Impact factor: 6.222

4.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension.

Authors:  Thomas T van Sloten; Patrick C Souverein; Coen DA Stehouwer; Johanna Hm Driessen
Journal:  J Psychopharmacol       Date:  2022-04-07       Impact factor: 4.562

5.  Associations of Cardiovascular Agents and Metformin with Depression Symptoms: A Cross-Sectional Analysis from the HUNT Study, Norway.

Authors:  Ivana Bojanić; Ottar Bjerkeset; Lana J Williams; Michael Berk; Erik R Sund; Hege Sletvold
Journal:  Drugs Real World Outcomes       Date:  2022-07-18

6.  Language-agnostic pharmacovigilant text mining to elicit side effects from clinical notes and hospital medication records.

Authors:  Benjamin Skov Kaas-Hansen; Davide Placido; Cristina Leal Rodríguez; Hans-Christian Thorsen-Meyer; Simona Gentile; Anna Pors Nielsen; Søren Brunak; Gesche Jürgens; Stig Ejdrup Andersen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-07-26       Impact factor: 3.688

Review 7.  Management of Congenital Long-QT Syndrome: Commentary From the Experts.

Authors:  Lee L Eckhardt; Elizabeth S Kaufman; Michael J Ackerman; Peter F Aziz; Elijah R Behr; Marina Cerrone; Mina K Chung; Michael J Cutler; Susan P Etheridge; Andrew D Krahn; Steven A Lubitz; Marco V Perez; Silvia G Priori; Jason D Roberts; Dan M Roden; Eric Schulze-Bahr; Peter J Schwartz; Wataru Shimizu; M Benjamin Shoemaker; Raymond W Sy; Jeffrey A Towbin; Sami Viskin; Arthur A M Wilde; Wojciech Zareba
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-07-09

8.  β-Blockers and the Risk of Depression: A Matched Case-Control Study.

Authors:  Delia Bornand; Daphne Reinau; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2022-01-19       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.